APA (7th ed.) Citation

Blonda, A., Facey, K., Van de Vijver, I., Denier, Y., Huys, I., & Simoens, S. (2025). OP81 Outcome-Based Managed Entry Agreements For Rare Disease Therapies: Learnings From The Belgian Experience. International Journal of Technology Assessment in Health Care, 41, S37. https://doi.org/10.1017/S0266462325101359

Chicago Style (17th ed.) Citation

Blonda, Alessandra, Karen Facey, Inneke Van de Vijver, Yvonne Denier, Isabelle Huys, and Steven Simoens. "OP81 Outcome-Based Managed Entry Agreements For Rare Disease Therapies: Learnings From The Belgian Experience." International Journal of Technology Assessment in Health Care 41 (2025): S37. https://doi.org/10.1017/S0266462325101359.

MLA (9th ed.) Citation

Blonda, Alessandra, et al. "OP81 Outcome-Based Managed Entry Agreements For Rare Disease Therapies: Learnings From The Belgian Experience." International Journal of Technology Assessment in Health Care, vol. 41, 2025, p. S37, https://doi.org/10.1017/S0266462325101359.